Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03887741 · ClinicalTrials.gov registry record · Phase 1
Plasmapheresis Versus Plasma Infusion from Young APOE3 Homozygotes Into MCI APOE4 Homozygotes to Slow Disease Progression
A Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT03887741: Completed Phase 1 study, sponsored by Mayo Clinic.
NCT03887741 is a Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 3 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03887741, a Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
Determine safety of plasma infusion or exchange in APOE 44 patients.
Primary Outcome
Number of adverse events reported
Interventions
- BIOLOGICAL Plasmapheresis
- BIOLOGICAL Plasma infusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2021-09-15 |
| Est. Completion | 2024-02-16 |
| Phase | Phase 1 |
What the finished NCT03887741 record still lists
NCT03887741 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 2 interventions - of which Plasmapheresis is the first listed.
NCT03887741 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03887741 about?
NCT03887741 is a clinical study titled "Plasmapheresis Versus Plasma Infusion from Young APOE3 Homozygotes Into MCI APOE4 Homozygotes to Slow Disease Progression". Determine safety of plasma infusion or exchange in APOE 44 patients.
What is the current status of trial NCT03887741?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2021-09-15. Estimated completion is 2024-02-16.
What interventions are being tested in trial NCT03887741?
The interventions under investigation include: Plasmapheresis (BIOLOGICAL), Plasma infusion (BIOLOGICAL).
Who is sponsoring clinical trial NCT03887741?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03887741's enrollment target sits among peer trials
3 1999th of 2000 higher than 1 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI